- Home
- PNI vs ICCC Comparison
PNI vs ICCC Comparison
Compare PNI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- ICCC
- Stock Information
- Founded
- PNI 2002
- ICCC 1982
- Country
- PNI United States
- ICCC United States
- Employees
- PNI N/A
- ICCC N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- ICCC Health Care
- Exchange
- PNI Nasdaq
- ICCC Nasdaq
- Market Cap
- PNI 73.0M
- ICCC 60.1M
- IPO Year
- PNI N/A
- ICCC 1987
- Fundamental
- Price
- PNI $6.59
- ICCC $6.40
- Analyst Decision
- PNI
- ICCC
- Analyst Count
- PNI 0
- ICCC 0
- Target Price
- PNI N/A
- ICCC N/A
- AVG Volume (30 Days)
- PNI 26.4K
- ICCC 8.2K
- Earning Date
- PNI 01-01-0001
- ICCC 08-14-2025
- Dividend Yield
- PNI 4.76%
- ICCC N/A
- EPS Growth
- PNI N/A
- ICCC N/A
- EPS
- PNI N/A
- ICCC 0.20
- Revenue
- PNI N/A
- ICCC $28,274,756.00
- Revenue This Year
- PNI N/A
- ICCC N/A
- Revenue Next Year
- PNI N/A
- ICCC N/A
- P/E Ratio
- PNI N/A
- ICCC $30.50
- Revenue Growth
- PNI N/A
- ICCC 21.75
- 52 Week Low
- PNI $6.03
- ICCC $3.34
- 52 Week High
- PNI $7.89
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- PNI 48.16
- ICCC 52.83
- Support Level
- PNI $6.49
- ICCC $6.10
- Resistance Level
- PNI $6.62
- ICCC $6.30
- Average True Range (ATR)
- PNI 0.06
- ICCC 0.26
- MACD
- PNI 0.01
- ICCC 0.01
- Stochastic Oscillator
- PNI 49.00
- ICCC 44.64
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.